Source - GNW

Oslo, 17 October 2016: Targovax (OSE: TRVX, or "the Company"), a clinical stage company developing targeted immunotherapy treatments for cancer patients, announces that the Company will be presenting at the Changing the Face of Modern Medicine: Stem Cells & Gene Therapy symposium, hosted by the European Society of Gene and Cell Therapy (ESGCT) and the International Society for Stem Cell Research (ISSCR).

  • Session name: SESSION 6c: Cancer gene therapy
  • Presentation title: OR52: Anti-tumor potency of cancer vaccine ONCOS-102 in the treatment of malignant mesothelioma in pre-clinical and clinical studies
  • Date: 21 October 2016
  • Time: 09:00 CET
  • Participants: Lukasz Kuryk (Senior Research Scientist, Targovax)
  • Venue: Firenze Fiera Congress Center, Florence, Italy

For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: [email protected]

Øystein Soug, CFO
Phone: +47 90 6565 25
Email: [email protected]

Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: [email protected]

Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]

About Targovax

Arming the patient's immune system to fight cancer

Targovax (OSE: TRVX) is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

In July 2016 the Company listed its shares on Oslo Axess, securing funding for further development of the Company's ongoing and planned trials.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via Globenewswire